Herzuma and Truxima biosimilars to be distributed in Australia by Celltrion and to hospitals by Juno Pharmaceuticals.
Celltrion Healthcare (Celltrion) has entered into a partnership with Juno Pharmaceuticals (Juno) ( not to be confused with Juno Therapeutics) to market the trastuzumab biosimilar Herzuma and rituximab biosimilar Truxima in Australia. The company also launched Herzuma in Iraq. Under this co-marketing partnership, Celltrion Healthcare Australia the Marketing Authorization holder in Australia for Herzuma and Truxima will distribute the products in the market. Juno, a leading hospital supplier in Australia, will be responsible for sales promotion and providing hospital contracting services to Australian hospital customers.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins